BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38702019)

  • 1. Photo-regulated PROTACs: A novel tool for temporal control of targeted protein degradation.
    Xu H; Ohoka N; Inoue T; Yokoo H; Demizu Y
    Bioorg Med Chem Lett; 2024 Jul; 107():129778. PubMed ID: 38702019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
    Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
    Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies.
    Sincere NI; Anand K; Ashique S; Yang J; You C
    Molecules; 2023 May; 28(10):. PubMed ID: 37241755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
    Hu R; Wang WL; Yang YY; Hu XT; Wang QW; Zuo WQ; Xu Y; Feng Q; Wang NY
    Eur J Med Chem; 2022 Jan; 227():113922. PubMed ID: 34700270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4.
    Maneiro MA; Forte N; Shchepinova MM; Kounde CS; Chudasama V; Baker JR; Tate EW
    ACS Chem Biol; 2020 Jun; 15(6):1306-1312. PubMed ID: 32338867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Near-Infrared-Activatable PROTAC Nanocages for Controllable Target Protein Degradation and On-Demand Antitumor Therapy.
    He Q; Zhou L; Yu D; Zhu R; Chen Y; Song M; Liu X; Liao Y; Ding T; Fan W; Yu W
    J Med Chem; 2023 Aug; 66(15):10458-10472. PubMed ID: 37279091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.
    Yokoo H; Tsuji G; Inoue T; Naito M; Demizu Y; Ohoka N
    Bioorg Chem; 2024 Apr; 145():107204. PubMed ID: 38377822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alkenyl oxindole is a novel PROTAC moiety that recruits the CRL4DCAF11 E3 ubiquitin ligase complex for targeted protein degradation.
    Wang Y; Wei T; Zhao M; Huang A; Sun F; Chen L; Lin R; Xie Y; Zhang M; Xu S; Sun Z; Hong L; Wang R; Tian R; Li G
    PLoS Biol; 2024 May; 22(5):e3002550. PubMed ID: 38768083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivering on Cell-Selective Protein Degradation Using Chemically Tailored PROTACs.
    Yao R; Luo T; Wang M
    Chembiochem; 2023 Oct; 24(19):e202300413. PubMed ID: 37496112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydrogen Peroxide-Inducible PROTACs for Targeted Protein Degradation in Cancer Cells.
    Yu D; Fan H; Zhou Z; Zhang Y; Sun J; Wang L; Jia Y; Tian J; Campbell A; Mi W; Sun H
    Chembiochem; 2023 Sep; 24(17):e202300422. PubMed ID: 37462478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
    Reboud-Ravaux M
    Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors.
    Yang C; Yang Y; Li Y; Ni Q; Li J
    J Am Chem Soc; 2023 Jan; 145(1):385-391. PubMed ID: 36542856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras through iRGD Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer.
    He S; Fang Y; Wu M; Zhang P; Gao F; Hu H; Sheng C; Dong G
    J Med Chem; 2023 Dec; 66(24):16828-16842. PubMed ID: 38055861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early evaluation of opportunities in oral delivery of PROTACs to overcome their molecular challenges.
    Yang W; Saboo S; Zhou L; Askin S; Bak A
    Drug Discov Today; 2024 Feb; 29(2):103865. PubMed ID: 38154757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer Selective Target Degradation by Folate-Caged PROTACs.
    Liu J; Chen H; Liu Y; Shen Y; Meng F; Kaniskan HÜ; Jin J; Wei W
    J Am Chem Soc; 2021 May; 143(19):7380-7387. PubMed ID: 33970635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective degradation of BRD4 suppresses lung cancer cell proliferation using GSH-responsive PROTAC precursors.
    Fan H; Zhou Z; Yu D; Sun J; Wang L; Jia Y; Tian J; Mi W; Sun H
    Bioorg Chem; 2023 Nov; 140():106793. PubMed ID: 37683536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Light-Induced Protein Degradation with Photocaged PROTACs.
    Xue G; Wang K; Zhou D; Zhong H; Pan Z
    J Am Chem Soc; 2019 Nov; 141(46):18370-18374. PubMed ID: 31566962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted protein degradation via intramolecular bivalent glues.
    Hsia O; Hinterndorfer M; Cowan AD; Iso K; Ishida T; Sundaramoorthy R; Nakasone MA; Imrichova H; Schätz C; Rukavina A; Husnjak K; Wegner M; Correa-Sáez A; Craigon C; Casement R; Maniaci C; Testa A; Kaulich M; Dikic I; Winter GE; Ciulli A
    Nature; 2024 Mar; 627(8002):204-211. PubMed ID: 38383787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy.
    Bhole RP; Kute PR; Chikhale RV; Bonde CG; Pant A; Gurav SS
    Bioorg Chem; 2023 Oct; 139():106720. PubMed ID: 37480814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.